Home・Список акций・Geron Corp

Geron Corp

Открыт

СекторЗдравоохранение

1.61 20.15

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.34

Макс.

1.6099999999999999

Ключевые показатели
By Trading Economics
Доход	25M -3.6M
Продажи	3.8M 52M
Прибыль на акцию	-0.005
Рентабельность продаж	-7.026
Сотрудники	258
EBITDA	27M 3.8M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+198.51% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-185M 821M
Предыдущая цена открытия	-18.54
Предыдущая цена закрытия	1.61

Новостные настроения

By Acuity

20%

80%

55 / 340 Рейтинг в Healthcare

Geron Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 23:36 UTC

Geron Corp shares are lower in after-market trading, nearing the bottom of their one-month range and below the 20-day moving average.

3 авг. 2026 г., 23:06 UTC

Geron Corp shares are lower in after-market hours, continuing a steady decline since Monday's close and remaining below the 20-day moving average.

31 июл. 2026 г., 20:02 UTC

Geron Corp shares are lower as the Biotechnology sub-sector declines. The stock pulled back from an earlier session high, finishing below its 20-day moving average.

30 июл. 2026 г., 20:56 UTC

Geron Corp shares are higher in after-market hours, influenced by positive corporate earnings amid broader market uncertainty following the Federal Reserve's interest rate decision.

29 июл. 2026 г., 19:32 UTC

Macro Event

Geron Corp shares are lower as market volatility rises following the Federal Reserve's interest rate decision amid ongoing economic growth and inflation concerns.

28 июл. 2026 г., 18:51 UTC

Shares of Geron Corp are lower today amid broader market volatility and uncertainty regarding Federal Reserve decisions. The stock declined since Monday's close.

27 июл. 2026 г., 23:16 UTC

Geron Corp shares are lower in after-market trading, despite earlier gains, with no specific company news driving the decline.

24 июл. 2026 г., 19:46 UTC

Geron Corp shares are lower in Friday's session amid broader market volatility and uncertainty from fluctuating oil prices and new U.S. tariffs.

23 июл. 2026 г., 10:11 UTC

Shares of Geron Corp are higher in pre-market hours, trading above their 20-day moving average. No specific company news was identified.

22 июл. 2026 г., 18:51 UTC

Geron Corp shares are lower today amid broader market trends, as crude oil prices surge due to geopolitical tensions.

21 июл. 2026 г., 23:41 UTC

Geron Corp shares are lower in after-market trading, declining to their lowest point since Tuesday's close. No specific news was identified to explain the drop.

20 июл. 2026 г., 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

Сравнение c конкурентами

Изменение цены

Geron Corp Прогноз

Целевая цена

By TipRanks

198.51% рост

Прогноз на 12 месяцев

Средняя 4 USD 198.51%

Максимум 5 USD

Минимум 3 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Geron Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

4 ratings

Покупка

Удержание

Продажа

Основано на мнении 4 аналитиков, присваивавших рейтинги акциям Geron Corp – Данные за последние 3 месяца.

Настроения

By Acuity

55 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.